A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients

被引：0
|
作者：
Haeberle, L. [1 ]
Erber, R. [2 ]
Gass, P. [1 ]
Hein, A. [1 ]
Jud, S. M. [1 ]
Langemann, H. [1 ]
Rauh, C. [1 ]
Hack, C. C. [1 ]
Schulz-Wendtland, R. [3 ]
Hartmann, A. [2 ]
Beckmann, M. W. [1 ]
Lux, M. P. [1 ]
Fasching, P. A. [1 ]
机构：
[1] Erlangen Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany
[2] Erlangen Univ Hosp, Inst Pathol, Erlangen, Germany
[3] Erlangen Univ Hosp, Inst Radiol, Erlangen, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226P
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Characteristics of breast cancer patients with pathological complete response after neoadjuvant chemotherapy
    Kolacinska, Agnieszka
    Blasinska-Morawiec, Maria
    Dowgier-Witczak, Izabela
    Kordek, Radzislaw
    Morawiec, Zbigniew
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2010, 9 (05): : 300 - 304
  • [12] Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients
    M. E. Tesch
    S. K. Chia
    C. E. Simmons
    N. LeVasseur
    Breast Cancer Research and Treatment, 2021, 187 : 167 - 176
  • [13] Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients
    Tesch, M. E.
    Chia, S. K.
    Simmons, C. E.
    LeVasseur, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 167 - 176
  • [14] A Novel 5-gene Score to Predict Complete Pathological Response to Neoadjuvant Chemotherapy in ER-Positive/HER2-Negative Breast Cancer
    Oshi, Masanori
    Angarita, Fernando A.
    Tokumaru, Yoshihisa
    Yan, Li
    Endo, Itaru
    Takabe, Kazuaki
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S348 - S348
  • [15] A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Oshi, Masanori
    Gandhi, Shipra
    Angarita, Fernando A.
    Kim, Tae Hee
    Tokumaru, Yoshihisa
    Yan, Li
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (07): : 3611 - +
  • [16] ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR).
    Earl, Helena Margaret
    Hiller, Louise
    Blenkinsop, Clare
    Grybowicz, Louise
    Vallier, Anne-Laure
    Abraham, Jean
    Thomas, Jeremy
    Provenzano, Elena
    Hughes-Davies, Luke
    McAdam, Karen
    Chan, Steve
    Ahmad, Rizvana
    Hickish, Tamas
    Houston, Stephen
    Rea, Daniel
    Bartlett, John M. S.
    Caldas, Carlos
    Cameron, David A.
    Dunn, Janet
    Hayward, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [17] Prediction of pathological complete response by microRNA in breast cancer patients treated with neoadjuvant chemotherapy
    Shimomura, Akihiko
    Shiino, Sho
    Kawauchi, Junpei
    Takizawa, Satoko
    Ichikawa, Makiko
    Matsuzaki, Juntaro
    Sakamoto, Hiromi
    Kinoshita, Takayuki
    Tamura, Kenji
    Ochiya, Takahiro
    CANCER SCIENCE, 2018, 109 : 394 - 394
  • [18] Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer
    Charehbili, A.
    Van de Ven, S.
    Liefers, G. J.
    Smit, V. T.
    Wasser, M. N.
    Kranenbarg, E. M. Meershoek-Klein
    Van Leeuwen-Stok, A. E.
    Van de Velde, C. J. H.
    Nortier, J. W. R.
    Kroep, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S401 - S401
  • [19] High tumor grade might be associated with pathologic complete response after neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (02): : 1266 - 1266
  • [20] Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
    Issa-Nummer, Yasmin
    Darb-Esfahani, Silvia
    Loibl, Sibylle
    Kunz, Georg
    Nekljudova, Valentina
    Schrader, Iris
    Sinn, Bruno Valentin
    Ulmer, Hans-Ullrich
    Kronenwett, Ralf
    Just, Marianne
    Kuehn, Thorsten
    Diebold, Kurt
    Untch, Michael
    Holms, Frank
    Blohmer, Jens-Uwe
    Habeck, Joerg-Olaf
    Dietel, Manfred
    Overkamp, Friedrich
    Krabisch, Petra
    von Minckwitz, Gunter
    Denkert, Carsten
    PLOS ONE, 2013, 8 (12):
12345